

28 June 2024

Migraine Treatments

How many patients have been treated with the following drugs in the past 4 months:

- Atogepant (Aquipta)
- Erenumab (Aimovig)
- Eptinezumab (Vyepiti)
- Fremanezumab (Ajovy)
- Galcanezumab (Emgality)
- Rimegepant (Vydura)
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin)

Belfast Health and Social Care Trust does not have an electronic prescribing with this level of information to patient level and so we are unable to provide this information

How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant	30	
Erenumab		
Eptinezumab		
Fremanezumab		
Galcanezumab	40	
Rimegepant	15	2
Botulinum Toxin	121	



28 June 2024

We are seeking to understand the funding and delivery of Botox and anti-CGRP monoclonal antibody treatments (Ajoovy, Aimovig, Emgality, Vyepti, Vydura & Aquipta) for migraine. Could you please answer the following:

- **Does the trust commission/fund Botox treatment for migraine**

Yes

- **Does the trust commission/fund anti-CGRP treatments for migraine**

Yes

- **Does the trust actively provide Botox/anti-CGRP treatments for migraine as opposed to sending patients to another trust**

Yes

In case the trust does not provide these treatments, please provide the name of the trust to which you refer migraine patients for these treatments?

n/a

- **In case the trust actively provides Botox/anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.**

n/a